4.5 Article

Methylparaben stimulates tumor initiating cells in ER plus breast cancer models

Journal

JOURNAL OF APPLIED TOXICOLOGY
Volume 37, Issue 4, Pages 417-425

Publisher

WILEY
DOI: 10.1002/jat.3374

Keywords

methylparaben; parabens; mammospheres; Nanog; endocrine disruptor; breast cancer

Categories

Funding

  1. Susan G. Komen for the Cure
  2. National Cancer Institute [CA138488]
  3. West Cancer Center (Memphis, TN, USA)

Ask authors/readers for more resources

A body of epidemiological evidence implicates exposure to endocrine disrupting chemicals (EDCs) with increased susceptibility to breast cancer. To evaluate the physiological effects of a suspected EDC in vivo, we exposed MCF-7 breast cancer cells and a patient-derived xenograft (PDX, estrogen receptor positive) to physiological levels of methylparaben (mePB), which is commonly used in personal care products as a preservative. mePB pellets (4.4g per day) led to increased tumor size of MCF-7 xenografts and ER+ PDX tumors. mePB has been thought to be a xenoestrogen; however, in vitro exposure of 10nM mePB failed to increase MCF-7 cell proliferation or induction of canonical estrogen-responsive genes (pS2 and progesterone receptor), in contrast to 17-estradiol (E2) treatment. MCF-7 and PDX-derived mammospheres exhibited increased size and up-regulation of canonical stem cell markers ALDH1, NANOG, OCT4 and SOX2 when exposed to mePB; these effects were not observed for MDA-MB-231 (ER-) mammospheres. As tumor-initiating cells (TICs) are also believed to be responsible for chemoresistance, mammospheres were treated with either tamoxifen or the pure anti-estrogen fulvestrant in the presence of mePB. Blocking the estrogenic response was not sufficient to block NANOG expression in mammospheres, pointing to a non-classic estrogen response or an ER-independent mechanism of mePB promotion of mammosphere activity. Overall, these results suggest that mePB increases breast cancer tumor proliferation through enhanced TIC activity, in part via regulation of NANOG, and that mePB may play a direct role in chemoresistance by modulating stem cell activity. Copyright (c) 2016 John Wiley & Sons, Ltd. Methylparaben (mePB) is a common preservative in personal care products and food, and is thought to be a xenoestrogen. Herein, we demonstrate that mePB led to an increased tumor size of MCF-7 xenografts and ER+ PDX tumors in nude mice. Furthermore, mePB induces the size of mammospheres and induces the transcription of stem cell markers, including NANOG.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

An Orally Available Tubulin Inhibitor, VERU-111, Suppresses Triple-Negative Breast Cancer Tumor Growth and Metastasis and Bypasses Taxane Resistance

Shanshan Deng, Raisa I. Krutilina, Qinghui Wang, Zongtao Lin, Deanna N. Parke, Hilaire C. Playa, Hao Chen, Duane D. Miller, Tiffany N. Seagroves, Wei Li

MOLECULAR CANCER THERAPEUTICS (2020)

Article Oncology

Simultaneous Multi-Organ Metastases from Chemo-Resistant Triple-Negative Breast Cancer Are Prevented by Interfering with WNT-Signaling

Iram Fatima, Ikbale El-Ayachi, Hilaire C. Playa, Jackelyn A. Alva-Ornelas, Aysha B. Khalid, William L. Kuenzinger, Peter Wend, Jackelyn C. Pence, Lauren Brakefield, Raisa Krutilina, Daniel L. Johnson, Ruth M. O'Regan, Victoria Seewaldt, Tiffany N. Seagroves, Susan A. Krum, Gustavo A. Miranda-Carboni

CANCERS (2019)

Article Oncology

Pivarubicin Is More Effective Than Doxorubicin Against Triple-Negative Breast Cancer In Vivo

Leonard Lothstein, Judith Soberman, Deanna Parke, Jatin Gandhi, Trevor Sweatman, Tiffany Seagroves

ONCOLOGY RESEARCH (2020)

Article Endocrinology & Metabolism

GATA4 regulates mesenchymal stem cells via direct transcriptional regulation of the WNT signalosome

Aysha B. Khalid, Jacquelyn Pence, Sarocha Suthon, Jianjian Lin, Gustavo A. Miranda-Carboni, Susan A. Krum

Summary: GATA4 is a transcription factor that plays a role in osteoblast differentiation, with its knockout in mice resulting in decreased trabecular bone properties and reduced MSCs, along with decreased expression of WNT signalosome components.
Review Cell Biology

WNT5B in Physiology and Disease

Sarocha Suthon, Rachel S. Perkins, Vitezslav Bryja, Gustavo A. Miranda-Carboni, Susan A. Krum

Summary: WNT5B, closely related to WNT5A, plays crucial roles in cell migration, proliferation, and differentiation through the non-canonical pathway. It exhibits unique expression patterns and functions, influencing development, bone, adipose tissue, cardiac tissue, the nervous system, and more. Aberrations in WNT5B signaling contribute to diseases like osteoarthritis, osteoporosis, obesity, diabetes, neuropathology, chronic diseases, and cancers.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

Article Genetics & Heredity

Estrogen receptor alpha and NFATc1 bind to a bone mineral density-associated SNP to repress WNT5B in osteoblasts

Sarocha Suthon, Jianjian Lin, Rachel S. Perkins, John R. Crockarell, Gustavo A. Miranda-Carboni, Susan A. Krum

Summary: Genetic factors and estrogen deficiency contribute to the development of osteoporosis. The SNP rs2887571 correlates with WNT5B expression, with different mechanisms in each genotype. WNT5B suppresses alkaline phosphatase expression and activity, inhibiting osteoblast differentiation and mineralization. WNT5B inhibits osteoblast differentiation by activating the ROR1/2 signaling pathway and suppressing beta-catenin activity.

AMERICAN JOURNAL OF HUMAN GENETICS (2022)

Review Cell Biology

WNT5B in cellular signaling pathways

Rachel S. S. Perkins, Sarocha Suthon, Gustavo A. A. Miranda-Carboni, Susan A. A. Krum

Summary: In this article, the researchers review the current understanding of the regulation of WNT5B signal transduction and its roles in different types of Wnt signaling pathways.

SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2022)

Article Oncology

HIF-Dependent CKB Expression Promotes Breast Cancer Metastasis, Whereas Cyclocreatine Therapy Impairs Cellular Invasion and Improves Chemotherapy Efficacy

Raisa I. Krutilina, Hilaire Playa, Danielle L. Brooks, Luciana P. Schwab, Deanna N. Parke, Damilola Oluwalana, Douglas R. Layman, Meiyun Fan, Daniel L. Johnson, Junming Yue, Heather Smallwood, Tiffany N. Seagroves

Summary: This study identified creatine kinase, brain isoform (CKB) as a downstream gene of HIF-1 transcription factor that promotes invasion and metastasis in ER-negative breast cancer. Inhibition of CKB or creatine kinase activity using cCr suppressed cell invasion, invadopodia formation, and lung metastasis. In combination with conventional chemotherapy agents, cCr enhanced growth inhibition. These findings suggest that targeting CKB and cellular metabolism may be effective in treating metastatic breast cancer.

CANCERS (2022)

Article Genetics & Heredity

GATA4 and estrogen receptor alpha bind at SNPs rs9921222 and rs10794639 to regulate AXIN1 expression in osteoblasts

Sarocha Suthon, Rachel S. Perkins, Jianjian Lin, John R. Crockarell, Gustavo A. Miranda-Carboni, Susan A. Krum

Summary: This study reveals the molecular mechanism of SNP rs9921222 in regulating the expression of AXIN1 in human osteoblasts through GATA4 and ER alpha binding. The findings provide important insights into the genetic mechanism underlying osteoporosis and bone density regulation.

HUMAN GENETICS (2022)

Article Oncology

Sabizabulin, a Potent Orally Bioavailable Colchicine Binding Site Agent, Suppresses HER2+Breast Cancer and Metastasis

Raisa Krutilina, Kelli L. Hartman, Damilola Oluwalana, Hilaire C. Playa, Deanna N. Parke, Hao Chen, Duane D. Miller, Wei Li, Tiffany N. Seagroves

Summary: The study demonstrates the effectiveness of sabizabulin in inhibiting the growth and migration of HER2+ breast cancer cells, and inducing cell death. Sabizabulin is a promising alternative to taxanes for the treatment of HER2+ breast cancer, with similar anti-metastatic efficacy but better oral bioavailability and lower toxicity.

CANCERS (2022)

Review Cell Biology

The role of WNT10B in physiology and disease: A 10-year update

Rachel S. Perkins, Rishika Singh, Amy N. Abell, Susan A. Krum, Gustavo A. Miranda-Carboni

Summary: WNT10B, a member of the WNT family, plays a crucial role in controlling proliferation, stemness, pluripotency, and cell fate decisions through the WNT/beta-catenin signaling cascade. It is involved in various tissues and diseases, including bone, adipocytes, skin, hair, muscle, placenta, and the immune system. Mutations and polymorphisms of WNT10B are associated with phenotypes such as bone mineral density, obesity, pig litter size, dog elbow dysplasia, and cow body size. The regulation of WNT10B using microRNAs and long non-coding RNAs has been a focus of research, and therapeutic implications have also been discussed.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2023)

Meeting Abstract Oncology

WNT5B in osteosarcoma stem cells

Rachel S. Perkins, Sarocha Suthon, Gustavo A. Miranda-Carboni, Susan A. Krum

CANCER RESEARCH (2022)

Article Oncology

Breast Tumor Kinase (Brk/PTK6) Mediates Advanced Cancer Phenotypes via SH2-Domain Dependent Activation of RhoA and Aryl Hydrocarbon Receptor (AhR) Signaling

Amy R. Dwyer, Carlos Perez Kerkvliet, Raisa Krutilina, Hilaire C. Playa, Deanna N. Parke, Warner A. Thomas, Branden A. Smeester, Branden S. Moriarity, Tiffany N. Seagroves, Carol A. Lange

Summary: Research shows that in triple-negative breast cancer, the PTK6-driven signaling pathway mediates cell migration via RhoA and AhR signaling pathways, and plays a crucial role in lung metastasis.

MOLECULAR CANCER RESEARCH (2021)

Meeting Abstract Endocrinology & Metabolism

The effect of SNP rs2887571 (located in an estrogen receptor α binding site) on WNT5B function in bone

Sarocha Suthon, Gustavo A. Miranda-Carboni, Susan A. Krum

JOURNAL OF BONE AND MINERAL RESEARCH (2020)

Meeting Abstract Oncology

Colchicine binding site agents as potent tubulin inhibitors suppressing triple negative breast cancer

Shanshan Deng, Hao Chen, Raisa Krutilina, Najah G. Albadari, Tiffany N. Seagroves, Duane D. Miller, Wei Li

CANCER RESEARCH (2019)

No Data Available